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Abstract
Background: The risk of development of rheumatoid arthritis (RA) could be affected by immune activation in
obesity. Our objective was to evaluate the association between obesity in general, and abdominal obesity, and the
risk for subsequent development of RA.
Methods: In two large population-based, prospective cohorts, 557 cases (mean age at RA symptom onset 58, SD
10 years, 68% women) who subsequently developed RA and 1671 matched controls were identified. From a health
examination antedating symptom onset (median 5.5 years), collected data on body mass index (BMI; kg/m2), smoking
habits, and educational level was used in conditional logistical regression models. Corresponding regression models
were used to analyse the association between waist circumference measurements (cm) and RA development in a
subset of the population.
Results: BMI and waist circumference were associated with the risk of RA development, adjusted odds ratio (OR) (95%
CI), 1.13 (1.00, 1.28) per 5 kg/m2, and 1.02 (1.01, 1.04) per cm, respectively. An association was also observed for obesity
(BMI ≥30) OR 1.45 (1.07, 1.95), compared with BMI <25. After stratification for sex the associations were enhanced in
men, and attenuated in women. Among men with BMI above normal a 3–5 times increased risk for RA disease
development at 50 years of age or earlier was observed. Abdominal obesity with waist circumference >102 cm was
associated with a 2–3 times increased risk of RA, but not abdominal obesity (>88 cm) in women.
Conclusions: Obesity or abdominal obesity, respectively, was independently associated with a modest increase of the
risk for subsequent development of RA. This appeared to be relevant mainly for early RA disease onset among men.
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Background
At the time point when the first symptoms indicating
the onset of rheumatoid arthritis (RA) become apparent
for the individual, the immune system has been activated
for several years. This has been demonstrated by the
presence of anti-citrullinated peptide antibodies (ACPA),
rheumatoid factor (RF) and up-regulation of cytokines
and chemokines in blood samples [1, 2]. The pathogen-
esis of RA is largely unknown but heritability of approxi-
mately 50% for ACPA-positive and approximately 20%
for ACPA-negative RA has been shown, and environ-
mental factors are believed to interplay with genetic
factors during the early, pre-symptomatic stages [3].
Smoking and periodontal disease have been linked to de-
velopment of mainly seropositive RA [4, 5]. Obesity
could be another possible environmental risk factor due
to the pro-inflammatory nature of the adipose tissue,
but studies evaluating the association between body
mass index (BMI) and the risk of RA have shown
contradictory results [6–16].
Several studies have reported a positive association be-
tween obesity and the risk of RA development, overall
[8, 9, 11, 12, 16], in women [6, 10, 16], and in seronega-
tive RA disease development [9, 15]. Negative associa-
tions with obesity have been reported in two studies: in
RA [7] and ACPA-positive RA [15], respectively, in men.
Another two studies reported no statistically significant
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associations between BMI or BMI categories and RA
[13, 14]. The comparison between studies is hampered
by differences in methodology, but a recent meta-
analysis suggested a 30% increase in the risk of RA over-
all in obesity compared with normal weight [17].
Generally, BMI based on weight and height measure-
ments has limitations, as the proportion of body fat and
the location of the adipose tissue are of importance for
the risks associated with obesity. Visceral adipose tissue
depots are associated with metabolic disease, whereas
subcutaneous adipose tissue might have a protective ef-
fect on cardiovascular risk factors [18, 19]. Men with RA
have been shown to have increased deposition of intra-
abdominal fat and the proportion of visceral fat is asso-
ciated with cardiovascular risk factors [20]. Moreover,
differences have been observed between men and
women in body fat distribution or the associations be-
tween adipose tissue and comorbidity [18–21].
More profound knowledge of the tentative role of
obesity in the phases of RA before symptom onset could
improve the possibility of RA disease prevention in
high-risk individuals. Our aim was to investigate the as-
sociation between obesity as measured by BMI or waist
circumference and subsequent development of RA, tak-
ing gender into account, in a case–control study nested
within a large population-based, prospective cohort.
Methods
Two previously described cohorts, the Västerbotten
Intervention Programme (VIP) and the Northern
Sweden Multinational Monitoring of Trends and Deter-
minants in Cardiovascular Disease (MONICA) project,
were used for this nested case–control study [22, 23]. In
brief, the VIP was started in 1985, and since 1991 all in-
habitants of Västerbotten County in northern Sweden
have been invited to participate in VIP by having health
examination visits at 40, 50 and 60 years of age, mainly
for screening of cardiovascular risk factors and preven-
tion of cardiovascular morbidity. The Northern Sweden
MONICA project has performed population risk factor
surveys six times since 1986 in individuals aged 25–74
years. Both cohorts are characterized by a high participa-
tion rate (70–80%) and data on life style factors are col-
lected in a similar manner in both, making merging of
data from the two cohorts possible. Demographic and
anthropometric data and data on cardiovascular risk
factors are collected through standardised measurements
of weight (kg), height (cm) and blood pressure, and
through blood sampling and questionnaires. Waist cir-
cumference (cm) is measured in the MONICA cohort,
and was introduced as a measurement in VIP in 2004.
In Västerbotten County, with no private practitioners
in rheumatology, the only rheumatology clinic is the
University hospital, to which all individuals with newly
diagnosed or suspected RA are referred. In this setting
we identified all known patients with RA according to
the American Rheumatism Association (ARA) 1987 clas-
sification criteria [24], and who had one or more regis-
tered visit 1986–2013 as a participant in the VIP and/or
MONICA cohorts before the date of onset of RA symp-
toms (index date). Data from the health examinations
were retrieved (VIP, n = 508, and MONICA, n = 49), and
for every case, three controls (n = 1671) matched for age,
sex, cohort, year of health examination, and area of in-
habitance (rural/urban), were randomly selected from
the cohorts. For cases with more than one health exam-
ination (n = 141) the latest visit antedating RA symptom
onset was used.
Rheumatoid factor (RF) and ACPA at/after diagnosis were
analysed using clinical routine methods and the anti-cyclic
citrullinated peptide 2 (anti-CCP2) test (Eurodiagnostica,
Malmö, Sweden), respectively. The exposures were assessed
as BMI (kg/m2) and waist circumference (measured in
centimetres, available for 138/557 cases), respectively,
as registered at the health examinations. Abdominal
obesity was identified as waist circumference >102 cm
in men and >88 cm in women [25]. Body mass index
(BMI) was categorised according to the World Health
Organisation (WHO) criteria: obesity (≥30 kg/m2),
overweight (25–29.99 kg/m2), normal weight (18.5–
24.99 kg/m2), or underweight (<18.5 kg/m2). Information
on smoking habits and level of education was retrieved
from the questionnaire data.
Statistical methods
Descriptive data for cases and controls were summarized
and presented as proportions and means as appropriate.
Odds ratios for the risk of subsequent development of
RA associated with BMI, waist circumference, BMI
categories or the presence of abdominal obesity, were cal-
culated in conditional logistic regression models with add-
itional adjustment for smoking habits and educational
level. With <1% underweight cases and controls, the two
lowest BMI categories were combined and BMI <25 kg/m2
was used as the reference in analyses evaluating BMI cat-
egories. Analyses stratified for sex, age at RA symptom on-
set, and subsequent seropositive/seronegative RA disease
were performed. In a sensitivity analysis in women the OR
for RA associated with abdominal obesity using the same
definition as in men (>102 cm) was analysed. Another sen-
sitivity analysis was performed to evaluate the risk associ-
ated with obesity (BMI ≥30 kg/m2) in the presence/
absence of abdominal obesity (identified by waist circum-
ference) among both cases and controls. In this analysis
binary logistic regression models were used, with adjust-
ments for age, sex, year of health examination, cohort,
smoking and level of education, as the matching could not
be maintained in this analysis. In the stratified analyses the
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number of individuals in each stratum are presented in
Additional file 1: Tables S1–S3. Multiplicative interaction
was assessed by adding an interaction term to the regres-
sion models, and additive interaction by the method out-
lined by Zou [26]. Statistical calculations were performed
using IBM SPSS Statistics version 23 (IBM SPSS, IBM
Corp, NY, USA).
Results
The mean age (standard deviation, SD) at the time point
for the health examination was 51.9 (9.1) years and 68%
were women (Table 1). The mean (SD) time period be-
fore symptom onset was 6.5 (4.5) years and the mean
age at symptom onset was 58.3 (10.5) years (Table 1).
Smoking and a low level of education were more
common among cases, p < 0.001 and p < 0.01, respectively
(Table 1). Most cases (434/552, 85.6%) developed sero-
positive disease (Table 1); equally so for men and women
(84.2% and 86.2%, respectively). The proportion of sero-
positive disease was comparable in groups based on quar-
tiles of age at onset of RA symptoms (p = 0.152); >90% of
the cases (men and women) in the percentile with RA
symptom onset <50 years of age developed seropositive
RA disease.
In a conditional regression model comprising all cases
and controls BMI was associated with the risk of devel-
opment of RA: crude odds ratio (OR) 1.14 (95% confi-
dence interval, 1.01, 1.28) for every 5 kg/m2 increase in
BMI, and after adjustment for smoking habits and level
of education, OR 1.13 (1.00, 1.28) (Table 2). Analyses
Table 1 Characteristics of included cases and controls
Cases (n = 557) Controls (n = 1671)
Female sex, n (%) 379 (68) 1137 (68)
Data from the health examination visit
Age at examination (years), mean (SD) 51.9 (9.1) 51.9 (9.1)
Body mass index (kg/m2), mean (SD) 26.3 (4.3) 25.9 (4.0)
BMI category, n (%)
Underweight 5 (0.9) 15 (0.9)
Normal weight 220 (39.7) 748 (45.3)
Overweight 231 (41.7) 661 (40.1)
Obese 98 (17.7) 226 (13.7)
Smoking habits, n (%)
Non-smoker 177 (32.2) 812 (49.6)
Ex-smoker 175 (31.9) 498 (30.4)
Smoker 197 (35.9) 327 (20.0)
Educational level, n (%)
9 years or less 219 (39.8) 538 (32.8)
10–12 years 239 (43.5) 757 (46.1)
More than 12 years 92 (16.7) 346 (21.1)
Waist circumference (cm), mean (SD) (sample sizea: cases n = 138, controls n = 409) 92 (14) 89 (12)
Abdominal obesityb, n (%) (sample sizea: cases n = 138, controls n = 409) 54 (39.1) 131 (32.0)
Positive ACPA at examination, n (%) (sample sizec: cases n = 476, controls n = 800) 179 (37.6) 20 (2.5)
Data from the time point of RA symptom onset or later (only cases)
Time between the health examination visit and the onset of RA symptom (years)
Mean (SD) 6.4 (4.5)
Median (Q1, Q3) 5.5 (2.9, 8.9)
Age at RA symptom onset (years), mean (SD) 58.3 (10.5)
Positive ACPA at/after RA diagnosis, n (%) (sample sizec: cases n = 473) 380 (80.4)
Positive RF at/after RA diagnosis, n (%) (sample sizec: cases n = 552) 434 (78.6)
Positive ACPA and/or RF at/after RA diagnosis, n (%) (sample sizec: cases n = 554) 474 (85.6)
aWaist circumference was measured in the MONICA cohort, and was introduced as a measurement in the VIP cohort 2004. bAbdominal obesity was defined as
waist circumference >102 cm (men) or >88 cm (women). cACPA analysed in blood samples from the health examination was available for 476 cases and 800
controls. Anti-citrullinated peptide antibodies (ACPA) or rheumatoid factor (RF) at/after rheumatoid arthritis (RA) diagnosis was available for 473 cases and 552
cases, respectively, and either ACPA or RF at/after diagnosis was available for 554 cases. SD standard deviation, BMI body mass index
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stratified by sex resulted in similar, but not statistically
significant associations (Table 2).
Analyses of risk associated with BMI categories
overweight or obese
In models evaluating BMI, the category for obesity (OR
1.48 (1.12, 1.97)), but not for being overweight (OR 1.20
(0.96, 1.49)), was found to be associated with develop-
ment of RA. Adjustments for smoking and level of edu-
cation had a low impact on the estimates: the adjusted
OR for obesity was 1.45 (1.07, 1.95) and for being over-
weight it was 1.21 (0.96, 1.52) (Table 2). No interactions
was found between BMI and smoking (data not shown).
In stratified analyses, adjusted for smoking and level of
education, statistically significant associations were ob-
served between obesity and RA symptom onset ≤50 years
of age (OR 1.89 (1.02, 3.52)), and with seropositive dis-
ease (OR 1.40 (1.00, 1.96)) (Table 2).
Among men an association between obesity and RA
development was observed overall in men in the lowest
quartile of age at RA symptom onset, and for sero-
negative RA, respectively (Table 2). BMI above nor-
mal in men was associated with 3–5 times higher risk
of developing RA at an early age (Table 2). The OR
for development of seronegative RA among men was
high, although based on a small number of individuals
(see Additional file 1: Table S1). No statistically significant
association was observed among women (Table 2).
Analyses of the subset with waist circumference
measurements
Waist circumference measurement was available in a
subset comprising 138 cases and 409 controls; 68% were
Table 2 Associations between overweight or obesity and risk of development of rheumatoid arthritis
All Men Women
OR (95% CI) OR (95% CI) OR (95% CI)
All BMI (OR per 5 kg/m2 increase in BMI) 1.13 (1.00, 1.28) 1.17 (0.90, 1.50) 1.13 (0.98, 1.30)
BMI category vs. low-normal weight
All Obesity 1.45 (1.07, 1.95) 1.78 (1.01, 3.12) 1.37 (0.96, 1.95)
Overweight 1.21 (0.96, 1.52) 1.29 (0.84, 1.96) 1.21 (0.92, 1.59)
Normal-underweight Reference Reference Reference
Population divided by the age of the case at RA symptom onset:
≤50 years Obesity 1.89 (1.02, 3.52) 4.63 (1.14, 18.8) 1.39 (0.68, 2.87)
Overweight 1.43 (0.89, 2.29) 2.90 (1.08, 7.76) 1.20 (0.68, 2.10)
Normal-underweight Reference Reference Reference
51–59 years Obesity 1.37 (0.76, 2.47) 1.93 (0.68, 5.50) 1.16 (0.56, 2.40)
Overweight 1.10 (0.71, 1.72) 1.02 (0.47, 2.25) 1.23 (0.72, 2.13)
Normal-underweight Reference Reference Reference
60 − 65 years Obesity 1.62 (0.91, 2.89) 1.06 (0.35, 3.23) 1.96 (0.98, 3.92)
Overweight 1.08 (0.68, 1.71) 0.60 (0.25, 1.46) 1.28 (0.73, 2.25)
Normal-underweight Reference Reference Reference
≥66 years Obesity 1.14 (0.61, 2.14) 1.15 (0.32, 4.16) 1.20 (0.58, 2.48)
Overweight 1.29 (0.81, 2.01) 1.68 (0.67, 4.21) 1.17 (0.67, 2.05)
Normal-underweight Reference Reference Reference
Population divided by the serologic status for the case after RA diagnosis:
Seropositive RA Obesity 1.40 (1.00, 1.96) 1.33 (0.71, 2.50) 1.47 (0.99, 2.18)
Overweight 1.27 (0.99, 1.63) 1.15 (0.73, 1.84) 1.34 (0.99, 1.81)
Normal-underweight Reference Reference Reference
Seronegative RA Obesity 1.76 (0.88, 3.52) 12.3 (2.14, 71.1) 1.07 (0.47, 2.46)
Overweight 1.93 (0.51, 2.15) 3.44 (0.82, 14.5) 0.59 (0.27, 1.30)
Normal-underweight Reference Reference Reference
Analyses of the risk of development of rheumatoid arthritis (RA) associated with body mass index (BMI) for every 5 kg/m2 increase, or BMI categories of
overweight or obesity compared with normal-underweight. Results are presented in subjects overall, and divided by sex. Results from conditional logistic regression,
adjusted for education and smoking, in case–control sets matched for age, sex and year of examination. Analyses of BMI categories were also performed after dividing
the case–control sets by quartiles of the age of the case at onset of RA symptoms, or whether the case subsequently developed seropositive or seronegative RA disease.
OR odds ratio
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women. As the measuring of waist circumference was
introduced in the health examinations in VIP in later
years, individuals with waist circumference measurements
had been included at a later time point than individuals
without this measurement, with median year of examin-
ation 2004 and 1996, respectively (see Additional file 1:
Table S4). Among the cases 54 (39.1%) had abdominal
obesity, compared with 131 (32.0%) of the controls. Ab-
dominal obesity was more common among women; 38
(40.0%) of cases and 104 (37.3%) of the female controls
had waist circumference >88 cm.
Analyses of the risk of RA associated with waist meas-
urement indicated a 2% increase in the risk of RA
development for each centimetre increase in waist meas-
urement (adjusted OR 1.02 (1.01, 1.04)) overall. The risk
was enhanced in men (adjusted OR 1.05 (1.01, 1.09)). No
statistically significant association was observed in women
(Table 3). Abdominal obesity (using the cutoff >88
and >102 cm in women and men, respectively) overall
was not statistically significantly associated with RA devel-
opment (unadjusted OR 1.39 (0.93, 2.09), OR adjusted for
smoking and level of education 1.40 (0.92, 2.14)) (Table 3).
A three-fold increase in the risk of RA development
was observed in men with abdominal obesity (Table 3).
No association was observed among women (Table 3).
In this subset BMI was associated with RA overall,
and particularly in men (Table 3). Obesity defined as
BMI ≥30 kg/m2 compared with BMI <25 kg/m2 was
associated with the risk of RA development, overall,
in men and in seropositive RA disease, with risk esti-
mates indicating double to triple increased risk
(Table 3). Positive associations with RA development
overall were observed in both sexes and in both
seropositive and seronegative disease when comparing
obesity with non-obesity (Table 3).
Sensitivity analyses
Using the same cutoff value for abdominal obesity in
women as in men (waist circumference >102 cm), 18
(18.9%) of the female cases and 26 (9.3%) of the controls
were abdominally obese. Use of this definition resulted
in a model where abdominal obesity in women was asso-
ciated with double the risk of RA development (Table 4).
In an analysis evaluating abdominal obesity and
obesity identified by BMI in the same model, obesity
(BMI ≥30 kg/m2) was associated with RA among in-
dividuals with abdominal obesity, but not among
those with a normal waist circumference (Table 5).
Discussion
Several previous studies have shown positive associations
between obesity and RA development, mostly of moder-
ate strength and in various strata of age, sex, and sero-
logical status [6, 8–12, 15, 16]. A recent meta-analysis
identified a pooled risk estimate of 1.31, which is in par-
ity with our fully adjusted estimate of 1.45 [17].
Age at disease onset has rarely been considered before,
but the results from the Nurses’ Health Study indicated
a stronger association between obesity and RA develop-
ment at a younger age [6]. In the present study the asso-
ciation between obesity and RA was seen mainly for
early disease onset among men, and the Nurses’ Health
Study included women exclusively, which makes the re-
sults difficult to compare [6]. Interestingly, our results
contradict the results from a Swedish study in which
high BMI in some regression models were associated
Table 3 Associations between obesity and the risk of development of rheumatoid arthritis in the subset with available waist
circumference measurement




OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
BMI (OR per 5 kg/m2) 1.31 (1.05, 1.64) 1.91 (1.15, 3.19) 1.19 (0.92, 1.53) 1.28 (0.99, 1.65) 1.52 (0.88, 2.64)
Waist circumference (OR per cm) 1.02 (1.01, 1.04) 1.05 (1.01, 1.09) 1.01 (0.99, 1.04) 1.02 (1.00, 1.04) 1.02 (0.98, 1.07)
Abdominal obesity 1.40 (0.92, 2.14) 3.57 (1.50, 8.51) 1.04 (0.63, 1.71) 1.36 (0.85, 2.17) 1.21 (0.41, 3.62)
No abdominal obesity Reference Reference Reference Reference Reference
Obesity 2.95 (1.20, 3.51) 3.56 (1.27, 9.96) 1.68 (0.88, 3.23) 1.98 (1.07, 3.67) 2.18 (0.62, 7.67)
Overweight 0.84 (0.52, 1.36) 1.12 (0.41, 3.04) 0.77 (0.44, 1.35) 1.02 (0.60, 1.74) 0.31 (0.09, 1.07)
Normal or underweight Reference Reference Reference Reference Reference
Obesity 2.12 (1.35, 3.63) 3.37 (1.37, 8.31) 1.88 (1.02, 3.46) 1.96 (1.12, 3.45) 3.66 (1.15, 11.7)
No obesity Reference Reference Reference Reference Reference
Associations between abdominal obesity (measured by waist circumference) or being overweight and/or obese (as assessed by body mass index (BMI)) and the
risk of onset of rheumatoid arthritis (RA) in all individuals, men and women separately, or divided based on whether the patients (cases) later developed
seropositive or seronegative RA. In the subset the individuals with available measurements of waist circumference (from the MONICA cohort and from the VIP
cohort from 2004 and onwards) were included. Results from conditional logistic regression analyses are presented adjusted for education and smoking, in case–control
sets matched for age, sex, cohort, and year of health examination. Abdominal obesity was defined as a waist circumference ≥102 cm (men) or ≥88 cm (women). Obesity
was defined as BMI ≥30 kg/m2, and overweight as BMI >25 and <30 kg/m2. OR odds ratio
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with a reduced risk of RA in men, who compared with
our study, were examined at a higher age [7]. If obesity
acts as a strong trigger for disease onset at an early age
in predisposed men, the selection of older age at exam-
ination could theoretically have contributed to an appar-
ent protective effect. An apparently protective effect of
obesity on development of seropositive RA among men
was presented in the Swedish EIRA study [15]. The dif-
ferences between the present study and the other two
studies might be attributed to methodological differ-
ences, such as study design, data collection, or participa-
tion rates, or specific characteristics of the populations.
Our findings were further emphasised by the associ-
ation between waist circumference and RA development
overall and in men, to our knowledge not previously
evaluated or reported. A greater proportion of intra-
abdominal body fat, in which the production and secre-
tion of proinflammatory substances is most abundant,
has been suggested as a reason for more negative conse-
quences of obesity in men compared with women [21].
Extreme abdominal obesity in women, as evaluated in
the sensitivity analyses, was associated with RA develop-
ment, indicating that the distribution of fat and/or pro-
portion of visceral fat might be of importance also in
women. The subset of the study population with waist
circumference differed from the group who did not have
this measurement in several respects that often can be
linked to the difference in calendar time for the health
examination. In the more contemporary subset the im-
pact of obesity seemed to be stronger, and statistically
significant positive associations were observed in both
sexes and in both seropositive and seronegative disease,
depending on exposure definition.
The results indicate that abdominal obesity confers
extra information to the presence of obesity in determin-
ing the risk of RA. It also indicates that cutoff values for
estimation of cardiovascular risk might not be ideal for
RA risk calculations. Differences in fat distribution
(comparing individuals with similar BMI) or between life
style factors in different populations (i.e. geographical re-
gions), between the sexes, during aging, and over calendar
time, could hypothetically contribute to the conflicting re-
sults from previous studies. As previously mentioned
methodological differences make it difficult to perform
direct comparisons between studies in this field.
In the present study we could not find support for a
differentiated role for obesity according to the serologic
status of RA, as some previous studies have indicated
[7, 8, 15]. From this perspective we suggest that obes-
ity, abdominal obesity and/or factors related to these,
act as a trigger or drive on the inflammatory system(s), ra-
ther than exert a specific immunologic effect. Based on
serological status, we found no reason to conclude that
the RA disease that developed among men before 50 years
of age constituted a specific subset. Presence of ACPA
and/or RF was as common among the individuals who de-
veloped RA before 50 years of age as among cases with
later onset. This was observed also among men, the
stratum in which we found the strongest association be-
tween obesity and RA.
In spite of the strengths of the study, including the
prospective, population-based cohort with standardised
measurements that formed the basis of our study and
the well-defined RA diagnoses, there are some limita-
tions. The number of cases was low in some subgroups;
it may therefore be questionable to draw any firm con-
clusions from the association between obesity and sero-
negative RA in men. It can also not be ruled out that
unmeasured confounding or residual confounding could
affect the results. Measurement of waist circumference
was not available for all study participants. The health
examinations were performed mainly at 10-year intervals
from 40 years of age onwards, which limits the possibil-
ity of evaluating the exposure in individuals with disease
onset at a young age, which is observed more often
among women [27]. It also limits the possibility of longi-
tudinal evaluation of BMI development before the onset
of symptoms of RA.
Table 4 Risk for rheumatoid arthritis associated with abdominal
obesity, defined as waist circumference >102 cm, in women
Women
OR (95% CI)
All 2.28 (1.15, 4.55)
Divided by the serostatus of the case after RA diagnosis:
Seropositive RA 2.54 (1.18, 5.47)
Seronegative RA 1.44 (0.29, 7.16)
Sensitivity analyses of the associations between abdominal obesity in women
(n = 95 cases, and 279 controls), using the same cutoff as in men (waist
circumference >102 cm), and risk of onset of rheumatoid arthritis (RA). Analysed
overall and divided by serological status for rheumatoid factor and/or
anti-citrullinated peptide antibodies for the case after RA diagnosis,
respectively. Results from conditional logistic regression analyses adjusted
for education and smoking, in case–control sets matched for age, year of
examination and cohort
Table 5 Association between obesity and risk of rheumatoid
arthritis evaluated in presence/absence of abdominal obesity
All
OR (95% CI)
With abdominal obesity Obesity (BMI ≥30 kg/m2) 2.66 (1.26, 5.64)
Not obesity (BMI <30 kg/m2) Reference
No abdominal obesity Obesity (BMI ≥30 kg/m2) 0.48 (0.05, 4.40)
Not obesity (BMI <30 kg/m2) Reference
Sensitivity analysis of the association between obesity and the risk of onset of
rheumatoid arthritis in individuals divided on presence/absence of abdominal
obesity. Results from logistic regression models are presented adjusted for age,
sex, year of examination, cohort, education and smoking habits. Abdominal
obesity was defined as a waist circumference ≥102 cm (men) or ≥88 cm
(women). Obesity was defined as body mass index (BMI) ≥30 kg/m2
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Conclusions
In conclusion, in this case–control study, nested within
population-based prospective cohorts, we found obesity,
and abdominal obesity, respectively, to be associated
with a moderate increased risk of development of RA.
This appeared to be most marked among men, and both
obesity and being overweight were associated with early
RA development in men. Clinically, interventions for
obesity might be of importance for disease prevention in
individuals with a high risk of disease development.
In future research into environmental risk factors for
RA, efforts should be made to include all ages and
both sexes.
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The number of individuals with or without abdominal obesity in total
and as presented in the stratified analyses. Table S3. The number of
female individuals with or without abdominal obesity defined as waist
circumference >102 cm/ ≤102 cm. Table S4. Comparison of characteristics
between the individuals in the subset with waist circumference
measurement compared with the individuals without this
measurement. (DOCX 25 kb)
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